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Abstract: Telmisartan is indicated for the prevention of cardiovascular events in high-risk 
patients, based on comparable efficacy to the angiotensin-converting enzyme (ACE) inhibi-
tor, ramipril, in the ONgoing Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial (ONTARGET®) trial. However, tolerability must be considered when selecting 
treatments. This analysis compared the tolerability of telmisartan and ACE inhibitors using 
data pooled from 12 comparative, randomized studies involving 2564 telmisartan-treated 
patients and 2144 receiving ACE inhibitors (enalapril, lisinopril, or ramipril). Incidence rates 
of adverse events for the combined ACE inhibitor treatments and for telmisartan were similar 
(42.8% vs 43.9%, respectively) as were the rates of serious adverse events (1.8% vs 1.7% for 
telmisartan, respectively). Patients receiving ACE inhibitors had more cough (8.6% vs 2.6% 
with telmisartan, P , 0.0001). Results were similar irrespective of age, gender, or ethnicity. 
The adverse event of angioedema was observed in four patients (0.2%) receiving ACE inhibitors 
versus none with telmisartan (P = 0.043). There were small, numerical differences in serious 
adverse events. A total of 107 patients (5.0%) receiving ACE inhibitors and 93 patients (3.6%) 
receiving telmisartan discontinued treatment because of adverse events (P = 0.021); of these, 
32.7% and 5.4%, respectively, were discontinuations due to cough (relative risk reduction of 
88% [P , 0.0001] with telmisartan). Telmisartan and ACE inhibitors produced comparable 
blood pressure reductions at marketed doses. Telmisartan and ACE inhibitors are suitable for 
the prevention of cardiovascular events in high-risk patients, but telmisartan is better tolerated, 
particularly with regard to cough.
Keywords: adverse drug event, angiotensin-converting enzyme inhibitors, angiotensin II type 1 
receptor blockers, cough, hypertension
Introduction
Angiotensin II receptor blockers (ARBs) inhibit the deleterious angiotensin 
type 1 receptor-mediated vasoconstrictor, proliferative, and atherogenic effects of 
angiotensin II, which play important roles in the development of hypertension and 
cardiovascular disease.1 Like angiotensin-converting enzyme (ACE) inhibitors, ARBs 
provide effective blood pressure control in hypertensive patients.2 Furthermore, the 
ARB, telmisartan, has been shown to reduce cardiovascular mortality and morbidity in 
a broad population of high-risk patients.3 Moreover, ARBs are associated with greater 
adherence to therapy than ACE inhibitors,4,5 possibly due to their favorable tolerability 
profile.6 This latter finding has important clinical implications because treatment dis-
continuations are a major factor contributing to poor blood pressure control7 and are 
associated with increased cardiovascular risk and increased health care costs.8
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Telmisartan is an ARB that is indicated both for the 
  treatment of hypertension and for the reduction of cardiovascu-
lar morbidity in patients at high risk of cardiovascular events.9 
This latter indication is based on the results of the ONgoing 
Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial (ONTARGET®), which involved 25,620 patients 
with vascular disease or diabetes mellitus and end-organ dam-
age, in which telmisartan reduced the incidence of the primary 
endpoint (a composite of cardiovascular death, myocardial 
infarction, stroke, or hospitalization for heart failure) to the 
same extent as the established treatment for such patients, the 
ACE inhibitor, ramipril.3 In this study, more patients discon-
tinued treatment with ramipril than with telmisartan (23.7% vs 
21.0%, respectively), despite the fact that patients were screened 
for intolerance to ACE inhibitors before enrolment, and that 
strenuous efforts were made to retain patients in the study. It 
might be expected that a larger discrepancy between patient 
discontinuation rates should be seen in patients who had not 
been screened for ACE inhibitor intolerance, because cough 
associated with ACE inhibitors is known to be an important 
factor limiting adherence with these medications.10
We earlier presented evidence from a pooled analysis 
showing that telmisartan has a tolerability profile resembling 
placebo.11 However, to date, no study has compared in detail the 
tolerability of ARBs and ACE inhibitors. Furthermore, a recent 
analysis of treatment discontinuations from antihypertensive 
treatment has found significant within-class   differences.12 
In this analysis of 131,472 patients aged 40–80 years who 
lived in Lombardy, Italy, there was significant heterogeneity 
in treatment discontinuations among ACE inhibitors and, to 
a lesser extent, among ARBs. Thus, comparisons of toler-
ability between drugs within a class, as well as between drug 
classes, are important. In this study, we used pooled data from 
manufacturer-sponsored comparative studies of telmisartan 
in hypertensive patients to assess the incidence of adverse 
events with telmisartan compared with ACE inhibitors, as 
a class and individually. In contrast with previous analyses 
that have pooled published data from a wide variety of trials 
(eg, Bangalore et al10), we had access to the complete telmis-
artan trials database. This allowed us to analyze patient-level 
data, to ensure consistency in the recording of adverse events 
to avoid publication bias (which can introduce errors into 
analyses that rely on published sources).
Methods and materials
Study design
This analysis used safety data from all studies comparing 
telmisartan and ACE inhibitors in hypertensive patients, 
which were included in the Boehringer Ingelheim database 
and completed between 1994 and 2007. These comprised 
12 randomized studies (study designations 1236.1, 502.202, 
502.206, 502.210, 502.211, 502.214, 502.222, 502.223, 
502.317, 502.331, 502.391, 502.392). Two of the trials 
(502.222 and 502.223) selected patients who had previ-
ously experienced cough on ACE inhibitors. In all studies, 
treatment was given once daily in the morning. The trial-
specified duration of treatment ranged from 28 to 365 days. 
All trials were of monotherapy only and no antihypertensive 
treatment other than the study drug was allowed during the 
treatment period. The ONTARGET trial was not included 
because patients recruited to this study were prescreened for 
ACE inhibitor tolerance and the study allowed additional 
antihypertensive therapy. All studies were approved by local 
ethics committees and patients provided informed consent 
before enrolment.
Eight studies were double-blind, and four used a prospec-
tive randomized, open-label, blinded-endpoint design. All 
involved patients with mild-to-moderate hypertension, with 
most of the studies being defined as having diastolic blood 
pressure between 95 and 114 mmHg. Patients were random-
ized to treatment with telmisartan (at daily doses of between 
20 mg and 160 mg) or ACE inhibitors; the ACE inhibitors 
used were enalapril 5–20 mg; lisinopril 10–40 mg; or ramipril 
1.25–20 mg. In patients who had previously received antihy-
pertensive therapy, randomized treatment was preceded by a 
washout period, usually of 4 weeks’ duration, during which 
patients received placebo. Treatment was given at a fixed 
dose in seven studies, and following dose titration according 
to blood pressure responses in five studies.
Safety evaluation
An adverse event was defined as any untoward medical occur-
rence that was reported by a patient or identified during clini-
cal evaluation. Serious adverse events were defined as those 
that were fatal or life-threatening, or required hospitalization 
of the patient or extension of the period of hospitalization. 
All adverse events, whether reported spontaneously by the 
patient or detected by the investigator, that occurred during 
the treatment phase or within a day after discontinuation of 
treatment, were recorded and coded according to the Medical 
Dictionary for Regulatory Activities (MedDRA) v 8.1. The 
intensity and causality of adverse events were recorded by 
the investigators; drug-related adverse events were defined 
as events for which a causal relationship to the treatment 
had been suspected by the reporting or reviewing healthcare 
professional (usually the investigator or study monitor). 
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Multiple occurrences of a specific adverse event in an 
  individual patient were counted only once, whereas if a 
patient experienced more than one adverse event of different 
types, each event was included in the analysis.
Statistical analysis
Adverse event frequencies are reported as raw percentages 
and as occurrences per patient-year; the latter approach 
reflects differences in patient exposure to the drug and pro-
vides a standardized number of events observed in a patient 
treated for 1 year. Expressing data in terms of patient-years’ 
exposure enables physicians to identify long-term adverse 
events associated with a particular treatment, and facilitates 
comparisons between studies of different lengths.12 However, 
this concept assumes that the rate of events is constant over 
time, and may be misleading if this assumption is not met. 
If appropriate, differences in event rates were tested using 
the Chi-squared test and relative risk ratios were   calculated. 
The incidence of cough over time was presented as a 
Kaplan–Meier curve.
Results
The 12 studies included a total of 4708 patients, of whom 
2564 received telmisartan, 755 received enalapril, 220 
received lisinopril, and 1169 received ramipril. The patients’ 
baseline characteristics are summarized in Table 1. The dura-
tion of exposure to antihypertensive medication ranged from 
95.8 patient-years in patients receiving lisinopril to 698.0 
patient-years in telmisartan-treated patients (Table 2).
The overall incidence of patients with adverse events was 
37.7% (1.46 per patient-year) with enalapril, 69.1% (1.59 per 
patient-year) with lisinopril, 41.1% (1.82 per patient-year) 
with ramipril (combined ACE inhibitor incidence 42.8%, 
1.65 per patient-year) and 43.9% (1.61 per patient-year) 
with telmisartan (Table 3). The corresponding incidences 
of drug-related adverse events were 15.8% (0.61), 32.7% 
(0.75), 10.3% (0.45) (combined ACE inhibitor incidence 
14.5% [0.56]) and 10.2% (0.37), respectively. The incidences 
of the most common adverse events (those occurring in 
more than 1% of patients in either the telmisartan or ACE 
inhibitor groups) are summarized in Table 4. In general, the 
incidence per patient-year of these events was similar with 
both treatments.
However, the incidence of cough was significantly higher 
in patients receiving ACE inhibitors (8.6%, 0.33 per patient-
year) than in those receiving telmisartan (2.6%, 0.10 per 
patient-year). The incidence of cough over time is presented 
in Figure 1 (P , 0.0001 in log rank test). The incidence of 
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cough in patients receiving ACE inhibitors tended to be 
higher in women than in men, and also in Black or Asian 
patients (Figure 2). Telmisartan was associated with a lower 
incidence of cough than ACE inhibitors in all patient sub-
groups studied, irrespective of age, gender, or race (Figure 2). 
The relative risk reduction was broadly constant across all 
subgroups, although it was higher among the Asian patients 
(85%) than Black (75%) or White (69%) patients, comparable 
among women (68%) and men (70%), higher among those 
aged ,65 years (74%) than those aged $65 years (58%) and 
lower among ex-smokers (63%) than never smokers (72%) 
and among current smokers (77%).
The incidence of angioedema (considered a nonserious 
adverse event) was also statistically significantly higher with 
ACE inhibitors than with telmisartan: four patients (0.2%) 
receiving ACE inhibitors developed angioedema, whereas 
no telmisartan-treated patient did so (P = 0.043). The inci-
dence of upper respiratory tract infections was numerically 
higher with telmisartan than with ACE inhibitors, but the 
difference was not statistically significant (0.19 vs 0.14 per 
patient-year, respectively).
Adverse events considered to be drug-related were 
reported in 311 (14.5%) patients receiving ACE inhibitors 
and in 261 (10.2%) telmisartan-treated patients (P , 0.0001), 
giving a standardized incidence of 0.56 per patient-year for 
ACE inhibitors and 0.37 per patient-year for telmisartan 
(Table 3).
Serious adverse events were reported in 39 (1.8%) 
patients receiving ACE inhibitors and in 44 (1.7%) telmisar-
tan-treated patients, giving a standardized incidence of 0.07 
per patient-year for ACE inhibitors and 0.06 per patient-year 
for telmisartan (Table 3). There were small, numerical dif-
ferences in the incidence of serious adverse events between 
telmisartan and ACE inhibitors, and between individual 
ACE inhibitors. Overall, 107 patients (5.0%) receiving ACE 
inhibitors discontinued treatment because of adverse events, 
compared with 93 patients (3.6%) receiving telmisartan; this 
corresponds to a relative risk reduction of 27% (P = 0.021) in 
the telmisartan group. Cough was an important cause of treat-
ment discontinuation: 35 patients receiving ACE   inhibitors 
Table 2 Duration of exposure to antihypertensive medication
Enalapril 
(n = 755)
Lisinopril 
(n = 220)
Ramipril 
(n = 1169)
Combined ACE inhibitors 
(n = 2144)
Telmisartan 
(n = 2564)
Total exposure (patient-years) 194.9 95.8 264.7 555.3 698.0
Mean exposure (days) 94.3 159.0 82.7 94.6 99.4
Exposure range (days) 1–222 4–425 1–139 1–425 1–426
Abbreviation: ACE, angiotensin-converting enzyme.
withdrew because of cough (32.7% of all discontinuations 
due to adverse events), compared with only five (5.4%) 
telmisartan-treated patients, corresponding to a relative risk 
reduction of 88% (P , 0.0001) in the telmisartan group.
Although the focus of this analysis was on the safety and 
tolerability of telmisartan compared with ACE inhibitors, the 
efficacy of the two treatments was assessed by comparing 
the mean changes in systolic and diastolic blood pressure 
from baseline to endpoint. It should be noted that these 
data are provided for the sake of completeness, and should 
be treated with caution due to different study designs and 
small patient numbers in some groups. The blood pressure 
reductions achieved with telmisartan at marketed doses 
(40–80 mg) were comparable with those produced by ACE 
inhibitors (Table 5).
Discussion
This pooled analysis of 12 randomized, controlled studies 
with telmisartan and ACE inhibitors revealed that, although 
both ACE inhibitors and telmisartan are generally well tol-
erated (with a similar overall incidence of adverse events and 
serious adverse events), there were statistically significantly 
fewer discontinuations due to adverse events with   telmisartan. 
A strength of our study, compared with other assessments 
of the tolerability of ARBs and ACE inhibitors, is that we 
had access to a large pool of data from prospective trials in 
which adverse events were carefully assessed in a standard-
ized fashion. Thus, these data provide a robust assessment 
of the relative incidence of adverse events with these drugs 
in the clinical trial setting.
The most important finding is the precise estimate of the 
incidence of cough which, as expected, was significantly 
lower with telmisartan than with ACE inhibitors. Overall, 
cough occurred in 8.6% of patients treated with ACE inhibi-
tors, which is comparable with the 10.6% reported in a recent 
meta-analysis by Bangalore et al.10 By contrast, only 2.6% 
of telmisartan-treated patients reported cough as an adverse 
event. Telmisartan significantly reduced the risk of cough 
(by approximately 70%), and reduced discontinuations due 
to cough, compared with ACE inhibitors.
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The finding that telmisartan is associated with a lower 
incidence of cough than ACE inhibitors is clinically relevant 
because it is widely recognized that cough is an important 
factor limiting patient adherence to ACE inhibitor therapy.13 
This is perhaps not surprising; hypertension is often asymp-
tomatic and hence adverse effects of antihypertensive therapy 
may make patients unwilling to continue with a treatment 
that appears to deliver no tangible benefit but may markedly 
impair their quality of life.14 In our analysis, 1.6% of ACE 
inhibitor-treated patients withdrew from clinical trials because 
of cough, which is comparable with the rates reported in the 
meta-analysis of Bangalore et al.10 The rate of discontinua-
tions due to cough with ACE inhibitors was approximately 
eight times higher than the respective figure for telmisartan 
(0.19%, a relative risk reduction of 88% [P , 0.0001] in 
the telmisartan group), a finding that is consistent with the 
experience in the ONTARGET study. In ONTARGET, 
discontinuations due to cough were nearly four times more 
frequent with ramipril than with telmisartan (4.2% vs 1.1%, 
respectively), despite the fact that patients in ONTARGET 
were prescreened for ACE inhibitor tolerance.3
The large database from the studies included in this 
analysis provided an opportunity to investigate the patient 
characteristics associated with ACE inhibitor treatment-
related cough. Our results showed that ACE inhibitor-related 
cough tended to be more common in women, in Black or 
Asian patients, and in older patients, whereas smoking did 
not increase the incidence of cough. The latter finding differs 
from those of a previous study,15 which reported that smok-
ing was an independent risk factor for ACE inhibitor-related 
cough. Our finding that ACE inhibitor-related cough was 
more common in Asian patients is consistent with previous 
studies;15,16 indeed, Asian ethnicity has been included as a 
predictive factor in algorithms for estimating the risk of ACE 
inhibitor-related cough.17
A recent analysis has investigated the incidence of treat-
ment discontinuations due to adverse events in Asian and 
non-Asian patients in the ONTARGET study.18 Among telm-
isartan-treated patients, the overall incidence of discontinua-
tions due to adverse events was significantly lower in Asian 
than in non-Asian patients (6.6% vs 10.3%, P = 0.0001), 
whereas the corresponding figures in ramipril-treated patients 
were similar in both groups (11.4% vs 11.8%). However, 
in ramipril-treated patients, discontinuations due to cough 
were significantly more common in Asian than in non-Asian 
patients (6.1% vs 3.9%, P , 0.001). Overall, telmisartan 
reduced the risk of discontinuation due to cough by more 
than 70% (relative risk: 0.26, 95% confidence interval 
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[CI]: 0.21–0.33): similar risk reductions were seen both in 
Asian and non-Asian patients, although the absolute risk of 
cough was higher in Asian patients.
We were also able to compare the incidence of adverse 
events with three different ACE inhibitors. In the analysis 
of the 131,472-patient Lombardy database, discontinuations 
with ramipril were lower than with enalapril or lisinopril.12 In 
the current study, discontinuations with enalapril were lower 
than with ramipril. This likely reflects the different nature 
of the current analysis (which uses data from prospective, 
relatively short, and mostly blinded clinical trials), com-
pared with the Lombardy study (which was observational 
and followed patients for up to 30 months). The relatively 
low rate of discontinuations from ramipril in the Lombardy 
study may be due to the “popularity factor”, ie, the fact that, 
as a result of the Heart Outcomes Prevention Evaluation trial, 
ramipril is widely acknowledged as an established treatment 
to reduce cardiovascular risk. Although the Lombardy study 
found relatively low discontinuations with ramipril, it should 
be noted that a large proportion of elderly patients may be 
unwilling to take medication with proven cardiovascular 
benefit if it is associated with even mild adverse effects. For 
example, a questionnaire-based study of community-living 
older persons found that 88% would be willing to take medi-
cation that reduced 5-year cardiovascular risk from 20% to 
12%, but only 46% would still be willing if that medication 
was associated with daily fatigue and dizziness, even if this 
had no effect on function.19
Treatment adherence is critically important if the full 
benefits of cardiovascular risk reduction in hypertensive 
patients are to be attained. Among 18,806 newly diagnosed 
hypertensive patients treated for $35 years by primary care 
physicians in Italy, those who were most adherent ($80% of 
days covered) had reduced cardiovascular risk compared with 
those who had low adherence (#40% of days covered, hazard 
ratio: 0.62; 95% CI: 0.40–0.96; P = 0.032).20 In a cohort of 
nearly 60,000 patients in Québec, Canada, those with low 
adherence (,80% of days covered) were more likely to have 
coronary artery disease, cerebrovascular disease, or chronic 
heart failure within the 3-year follow-up period.21 Patients 
with low adherence were more likely to be hospitalized (odds 
ratio: 1.17, 95% CI: 1.12–1.22) and, among hospitalized 
patients, those with low adherence incurred increased costs 
of $3574 per person within the 3-year period. In Italy, lower 
adherence to diuretics versus ARBs has been estimated to 
0.14 Treatment
logrank test: P < 0.0001
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Figure 1 Proportion of patients with cough within 6 months of treatment in patients 
receiving ACE inhibitors or telmisartan.
Abbreviation: ACE, angiotensin-converting enzyme.
00 .1 0.2
Incidence of cough (per patient year of exposure)
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Figure 2 Incidence of cough in patients receiving ACE inhibitors or telmisartan, in relation to age, gender, race, and smoking history.
Abbreviation: ACE, angiotensin-converting enzyme.
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result in higher overall treatment costs of around €500 per 
patient per year, despite lower drug acquisition cost.22 In a 
recent study from the United States, adherence to antihyper-
tensive therapy was found to reduce average annual health 
care costs by almost US $4500 per patient.8
Better tolerability is only beneficial if combined with 
efficacy that is at least comparable. In this regard, telmisartan 
generally provides blood pressure reductions that are equal 
to or greater than those with ACE inhibitors. For example, 
telmisartan 80 reduced 24-hour ambulatory systolic/diastolic 
blood pressure more than ramipril 10 mg in a pooled analysis 
of two 6-week studies.23 Telmisartan 80 mg reduced sys-
tolic blood pressure and diastolic blood pressure more than 
enalapril 20 mg in a 12-week, placebo-controlled study that 
included 440 patients with mild-to-moderate hypertension.24 
Blood pressure reductions with telmisartan 40–80 mg were 
similar to those with enalapril 20–40 mg in an open-label, 
dose-titrated study.25 Similarly, a dose-titrated comparison 
of telmisartan 40–160 mmHg with lisinopril 10–40 mg 
found comparable blood pressure reductions between the 
two dosage regimens.26 In this study, we pooled these and 
other data to provide an estimate of blood pressure reductions 
for each of the drugs studied. The blood pressure-lowering 
data presented here should be treated with caution because 
the data come from trials with different designs, including 
inclusion criteria, treatment duration, and fixed versus flex-
ible dosing. Nevertheless, these pooled data broadly support 
at least comparable blood pressure-lowering efficacy with 
telmisartan compared with ACE inhibitors.
The efficacy of a medical treatment is the extent to which 
a drug has the ability to bring about its intended effect under 
ideal circumstances. Randomized clinical trials are   typically 
designed to assess efficacy. However, more relevant to daily 
clinical practice is a drug’s effectiveness, ie, the extent to 
which a drug achieves its intended effect in the usual clinical 
setting. In the ONTARGET trial, telmisartan was found to 
have a similar efficacy to ramipril in preventing cardiovas-
cular events in patients without hypertension but with addi-
tional atherothrombotic risk factors. Patients were screened 
for ACE inhibitor tolerance, and there were active efforts to 
ensure medication adherence and to retain patients on treat-
ment. Given the differences in discontinuations seen in the 
current study, it is possible that, in patients not screened for 
ACE inhibitor tolerability and without close monitoring, the 
effectiveness (rather than efficacy) of telmisartan for prevent-
ing cardiovascular events may be greater than ramipril.27
In summary, this analysis has shown that telmisartan is 
associated with a lower incidence of cough and fewer treat-
ment discontinuations due to cough, while having a similar 
or greater antihypertensive efficacy, compared with ACE 
inhibitors. Together with the ONTARGET study,3 which 
showed that telmisartan is as effective as ramipril in reducing 
cardiovascular mortality and morbidity in high-risk patients, 
these findings underline that telmisartan is suitable for the 
prevention of cardiovascular events in all high-risk patients, 
including those who are at risk of, or have a history of, ACE 
inhibitor-related cough.
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Table 5 Adjusteda mean (95% confidence interval) blood pressure at baseline and change from baseline, separated for fixed dose and 
titration design studies (only marketed doses included)
SBP DBP
Baseline Change Baseline Change
Fixed-dose design
  Enalapril 20 mg (n = 150) 157.0 (154.2, 159.8) –10.8 (–13.3, –8.3) 100.5 (99.5, 101.6) –9.3 (–10.8, –7.8)
  Lisinopril 20 mg (n = 25) 154.7 (149.0, 160.5) –18.8 (–25.0, –12.6) 96.7 (94.8, 98.5) –11.0 (–14.7, –7.3)
  ramipril 10 mg (n = 927) 155.3 (154.4, 156.1) –9.3 (–10.7, –7.8) 100.3 (100.0, 100.6) –8.0 (–8.9, –7.2)
  ramipril 20 mg (n = 123) 153.9 (151.7, 156.1) –11.1 (13.9, –8.2) 101.5 (100.8, 102.2) –9.0 (–10.8, –7.3)
  Telmisartan 40 mg (n = 112) 155.1 (152.5, 157.8) –13.2 (–16.1, –10.3) 101.4 (100.6, 102.2) –10.2 (–11.9, –8.4)
  Telmisartan 80 mg (n = 1150) 156.0 (155.2, 156.7) –14.1 (–15.2, –12.9) 100.3 (100.0, 100.6) –10.8 (-11.5, –10.1)
Titration designb
  Enalapril 20 mg (n = 468) 163.1 (161.8, 164.5) –17.6 (–19.1, –16.1) 98.9 (98.2, 99.6) –12.1 (–13.1, –11.1)
  Lisinopril 40 mg (n = 110) 151.0 (148.3, 153.7) –14.2 (–17.7, –10.8) 99.9 (99.1, 100.8) –7.4 (–9.5, –5.3)
  Telmisartan 80 mg (n = 578) 160.6 (159.4, 161.8) –19.0 (–20.3, –17.7) 99.5 (98.9, 100.0) –13.0 (–13.8, –12.2)
Notes: aAdjusted for baseline and study; bmaximum dose is given.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.
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